Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on March 9, 2016, reporting an event that occurred on March 3, 2016. The filing details a material definitive agreement entered into by ChromaDex Inc., a wholly owned subsidiary of the Company, with 5Linx Enterprises, Inc. regarding the supply and marketing rights of the NIAGEN® ingredient.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial statements such as revenue, profit, cash flow, or debt levels. Instead, it outlines specific financial obligations within the amended supply agreement:
- Minimum Purchase Obligation: For the years 2016 through 2017, 5Linx must take or pay for $1.52 million of NIAGEN®.
- Exclusivity Threshold: To retain exclusivity for the melt format in the MLM sales channel, 5Linx must purchase $4 million of NIAGEN® during the 2016-2017 period.
- Scope of Rights: Exclusivity is limited to the melt format in the Multi-Level Marketing (MLM) sales channel in the U.S., Canada, and the Philippines.
Material Changes Versus Prior Period
The Second Amendment significantly alters the terms of the original 2014 Supply Agreement and prior amendments:
- Reduction in Commitment: The minimum purchase requirement to retain exclusivity was reduced from $21 million (for the period April 1, 2015, to March 31, 2017) to $4 million for the 2016-2017 period.
- Scope Restriction: The amendment clarifies that exclusivity applies only to the melt format in the MLM channel, whereas prior terms included Energy Shots and broader channel rights.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of general risks. The primary contingency noted is that 5Linx must meet the $4 million purchase threshold to maintain its exclusive marketing rights. The Company indicated it will seek confidential treatment for certain terms of the agreement when filing its Quarterly Report on Form 10-Q for the quarter ended April 2, 2016.
Important Facts for Investor Verification
- Verify the impact of the reduced $4 million exclusivity threshold on ChromaDex's projected revenue from 5Linx for 2016 and 2017.
- Confirm whether 5Linx has met the $1.52 million "take or pay" obligation for the current period.
- Review the upcoming Form 10-Q (for the quarter ended April 2, 2016) for the full text of the agreement and any terms under confidential treatment.
- Assess the strategic shift from broader channel exclusivity to a focused MLM melt format strategy.